Literature DB >> 34748120

Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults.

Mateo Ziu1,2,3,4, Sharad Goyal5,6,7, Jeffrey J Olson5,6,7.   

Abstract

TARGET POPULATION: These recommendations apply to adult patients (18 years of age and above) with progressive/recurrent glioblastoma multiforme (pGBM) after first line combined multimodality treatment. QUESTION: Can re-irradiation (by using conventional radiotherapy, fractionated radiosurgery, or single fraction radiosurgery) be used in patients with pGBM after the first adjuvant combined multimodality treatment with radiation and chemotherapy? RECOMMENDATION: Level III: When the target tumor is amenable for additional radiation, re-irradiation is recommended as it provides improved local tumor control, as measured by best imaging response. Such re-irradiation can take the form of conventional fractionation radiotherapy, fractionated radiosurgery, or single fraction radiosurgery. LEVEL III: Re-Irradiation is recommended in order to maintain or improve a patient's neurological status and quality of life prior to any further tumor progression.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adult; Brain tumor; Glioblastoma; Glioma; Progressive; Radiation therapy; Radiosurgery; Recurrent

Mesh：

Year:  2021        PMID： 34748120     DOI： 10.1007/s11060-021-03857-w

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  22 in total

Review 1.  Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework.

Authors:  Michael E Sughrue; Tyson Sheean; Phillip A Bonney; Adrian J Maurer; Charles Teo
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

Review 2.  A Systematic Review and Meta-Analysis of Studies Examining the Use of Brain Laser Interstitial Thermal Therapy versus Craniotomy for the Treatment of High-Grade Tumors in or near Areas of Eloquence: An Examination of the Extent of Resection and Major Complication Rates Associated with Each Type of Surgery.

Authors:  Gene H Barnett; Jeffrey D Voigt; Manmeet S Alhuwalia
Journal:  Stereotact Funct Neurosurg       Date:  2016-06-21       Impact factor: 1.875

3.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

4.  Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.

Authors:  Klaus Müller; Guido Henke; Sophie Pietschmann; Stefaan van Gool; Steven De Vleeschouwer; André O von Bueren; Inge Compter; Carsten Friedrich; Christiane Matuschek; Gunther Klautke; Rolf-Dieter Kortmann; Thomas Hundsberger; Brigitta G Baumert
Journal:  J Neurooncol       Date:  2015-06-13       Impact factor: 4.130

Review 5.  Stereotactic Laser Interstitial Thermal Therapy for Recurrent High-Grade Gliomas.

Authors:  Ian Lee; Steven Kalkanis; Constantinos G Hadjipanayis
Journal:  Neurosurgery       Date:  2016-12       Impact factor: 4.654

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.

Authors:  Steven De Vleeschouwer; Steffen Fieuws; Stefan Rutkowski; Frank Van Calenbergh; Johannes Van Loon; Jan Goffin; Raf Sciot; Guido Wilms; Philippe Demaerel; Monika Warmuth-Metz; Niels Soerensen; Johannes E A Wolff; Sabine Wagner; Eckhart Kaempgen; Stefaan W Van Gool
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

Review 8.  The role of radiotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Samuel Ryu; John M Buatti; Ann Morris; Steven N Kalkanis; Timothy Charles Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-12       Impact factor: 4.130

Review 9.  The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Jeffrey J Olson; Lakshmi Nayak; D Ryan Ormond; Patrick Y Wen; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2014-04-17       Impact factor: 4.130

10.  Expert consensus on re-irradiation for recurrent glioma.

Authors:  Andra V Krauze; Albert Attia; Steve Braunstein; Michael Chan; Stephanie E Combs; Rainer Fietkau; John Fiveash; John Flickinger; Anca Grosu; Steven Howard; Carsten Nieder; Maximilian Niyazi; Lindsay Rowe; Dee Dee Smart; Christina Tsien; Kevin Camphausen
Journal:  Radiat Oncol       Date:  2017-12-01       Impact factor: 3.481
View more
  4 in total

Review 1.  Next-generation engineered nanogold for multimodal cancer therapy and imaging: a clinical perspectives.

Authors:  Madhusudhan Alle; Garima Sharma; Seung-Hwan Lee; Jin-Chul Kim
Journal:  J Nanobiotechnology       Date:  2022-07-02       Impact factor: 9.429

Review 2.  Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.

Authors:  Ruijia Liang; Cheng Wu; Shiming Liu; Wenyan Zhao
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 3.  Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era.

Authors:  Augusto Leone; Antonio Colamaria; Nicola Pio Fochi; Matteo Sacco; Matteo Landriscina; Giovanni Parbonetti; Matteo de Notaris; Giulia Coppola; Elena De Santis; Guido Giordano; Francesco Carbone
Journal:  Biomedicines       Date:  2022-08-09

4.  ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma.

Authors:  Giovanni Luca Gravina; Alessandro Colapietro; Andrea Mancini; Alessandra Rossetti; Stefano Martellucci; Luca Ventura; Martina Di Franco; Francesco Marampon; Vincenzo Mattei; Leda Assunta Biordi; Marit Otterlei; Claudio Festuccia
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.